Search

Resumo Fundamento A ablação da taquicardia atrial (TA) com local de ativação mais precoce próxima ao feixe de His é um desafio, devido ao risco de bloqueio de AV completo por sua proximidade ao sistema de His-Purkinje (SHP). Uma alternativa para minimizar esse risco é posicionar o cateter na cúspide não coronária (CNC), que é anatomicamente contígua à região para-Hissiana. Objetivos O objetivo deste estudo foi fazer uma revisão de literatura e avaliar as características eletrofisiológicas, a segurança e o índice de sucesso de aplicação de radiofrequência (RF) por cateter na CNC para o tratamento de TA para-Hissiana em uma série de casos. Métodos Avaliamos retrospectivamente dez pacientes (Idade: 36±10 anos) que foram encaminhados para ablação de taquicardia paroxística supraventricular (TPSV) e haviam sido diagnosticados com TA focal para-Hissiana confirmada por manobras eletrofisiológicas clássicas. Para a análise estatística, um P valor d

FUNDAMENTO: O manejo ideal da anticoagulação oral (ACO) no período pré- e pós-ablação de fibrilação atrial (FA) ainda é motivo de controvérsia. OBJETIVO: Comparar duas estratégias de anticoagulação: suspensão da warfarina com a utilização de heparina de baixo peso molecular (HBPM) e a realização da ablação sem a suspensão da warfarina, mantendo o RNI terapêutico (entre 2,0 e 3,0). MÉTODOS: 140 pacientes (pt) portadores de FA persistente/ permanente submetidos à ablação por cateter de FA foram divididos em dois grupos: no grupo I (70 pt), a warfarina foi suspensa cinco dias antes do procedimento e utilizada terapia de transição com HBPM (enoxaparina 1 mg/kg 2x/dia pré-ablação e 0,5 mg/kg 2x/dia após o procedimento); no grupo II (70 pt), a warfarina não foi suspensa e o procedimento foi realizado com RNI terapêutico. Ambos os grupos receberam heparina intravenosa (TCA > 350 seg) durante o procedimento. RESULTADOS: No Grupo I, observou-se complicação hemorrágica maior (1,4%) e 4 pt (5,7%) com complicações hemorrágicas menores. No Grupo II, 2 pt (2,8%) apresentaram complicações hemorrágicas menores e 1 pt apresentou sangramento maior; porém, este ocorreu após uso de HBPM por RNI < 2,0. Não houve complicação tromboembólica ou morte cardiovascular nos dois grupos após 16 ± 8 meses. CONCLUSÃO: A realização de ablação por cateter de FA sem a suspensão de ACO e RNI terapêutico é uma estratégia semelhante em segurança e eficácia quando comparada à tradicional transição com HBPM, evitando um período inicial pós-ablação de anticoagulação potencialmente inadequada. BACKGROUND: The ideal management of oral anticoagulation (OAC) before and after catheter ablation for atrial fibrillation (AF) is still controversial. OBJECTIVE: To compare two anticoagulation strategies for catheter ablation for AF: warfarin withholding and use of low-molecular-weight heparin (LMWH); and maintenance of warfarin and therapeutic INR (between 2.0 and 3.0). METHODS: 140 patients (pt) with persistent/permanent AF undergoing catheter ablation for AF were divided into two groups: Group I (70 pt), in which warfarin was withheld five days prior to the procedure and transition to LMWH was used (enoxaparin: 1 mg/kg 2x/day before ablation, and 0.5 mg/kg 2x/day after ablation); Group II (70 pt), in which warfarin was not withheld and the procedure was performed with therapeutic INR. Both groups received intravenous heparin (ACT > 350 seconds) during ablation. RESULTS: In Group I, one pt (1.4%) had a major hemorrhagic complication and four pts (5.7%) had minor hemorrhagic complications. In Group II, two pts (2.8%) had minor hemorrhagic complications and one pt had a major bleeding, which occurred after using LMWH due to INR < 2.0. None of the groups had thromboembolic complications or cardiovascular death over a period of 16 ± 8 months. CONCLUSION: Catheter ablation for AF without withholding OAC and with therapeutic INR is a strategy that has similar safety and efficacy when compared with the traditional transition to LMWH, avoiding the potentially inadequate anticoagulation of the initial post-ablation period.

Background— Long-term cessation of oral anticoagulation (OAC) after catheter ablation of atrial fibrillation (AF) has been deemed controversial. The safety of this management strategy in patients without recurrent AF and with historically elevated risks for thromboembolism remains largely unknown. In this study, we sought to evaluate the long-term results of OAC cessation after successful catheter ablation of AF. Methods and Results— OAC and antiarrhythmic drugs (AADs) were discontinued irrespective of AF type or baseline CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack) risk score in 327 patients (mean age, 63±13 years; 79% men) with drug-refractory AF after catheter ablation (mean CHADS 2 score, 1.89±0.95; median, 2.0). Patients with a CHADS 2 score of 2 (45.4%) and 3 (23.2%) accounted for 68.8% of this cohort. In patients with a high risk of recurrence or prior thromboembolic complications, OAC was continued for up to 6 to 12 months postablation and antiplatelet therapy was administered to all patients who maintained sinus rhythm upon OAC interruption. After a follow-up of 46±17 months (range, 13–82 months), 82% remained AF free (off AADs). Significant predictors of late AF recurrence ( P 40 mm (HR, 3.52), CHADS 2 score ≥2 (HR, 1.81), and early recurrences (HR, 5.52). No symptomatic ischemic cerebrovascular events were detected during follow-up despite interruption of OAC in 298 (91%) patients and AADs in 293 (89%) patients. Conclusions— No significant thromboembolic-related morbidity is observed when AADs and OAC are discontinued after successful catheter ablation of AF in patients with a CHADS 2 score ≤3 who are maintained on antiplatelet therapy during long-term follow-up.

FUNDAMENTO: A prevalência da fibrilação atrial, os gastos com o sistema de saúde e a elevada morbidade e mortalidade associadas a ela, têm justificado a procura por novas abordagens terapêuticas. OBJETIVO: Avaliar a reprodutibilidade da técnica cirúrgica, a segurança e os resultados inicias da cirurgia vídeo-assistida para a ablação da fibrilação atrial isolada com radiofrequência bipolar. MÉTODOS: Dez pacientes (90% homens) com fibrilação atrial (50% paroxística) sintomática e refratária à terapia medicamentosa, sem doença cardíaca que requeresse cirurgia concomitante, foram submetidos à ablação da arritmia guiada por toracoscopia, no período de maio de 2007 a maio de 2008. Variáveis clínicas, laboratoriais e de imagem foram prospectivamente coletadas antes, durante e no seguimento pós-operatório. RESULTADOS: A cirurgia foi realizada conforme o planejado em todos os pacientes. Não houve lesão iatrogênica de estruturas intratorácicas ou óbitos. No seguimento médio de seis meses, 80% dos pacientes estão livres de fibrilação atrial. Houve melhora significativa dos sintomas de insuficiência cardíaca classe funcional New York Heart Association (2,4 ± 0,5 para 1,6 ± 0,7; p = 0,011). Não houve evidência de estenose de veias pulmonares à angiotomografia, nesta série. CONCLUSÃO: A cirurgia vídeo-assistida para o tratamento da fibrilação atrial é reprodutível e segura. Há melhora evolutiva dos sintomas de insuficiência cardíaca após a cirurgia. BACKGROUND: The prevalence of atrial fibrillation, expenses with the healthcare system and the associated high morbidity and mortality have justified the search for new therapeutic approaches. OBJECTIVE: To evaluate the reproducibility of the surgical technique, its safety and the initial outcome of the video-assisted surgery for the isolated atrial fibrillation ablation with bipolar radiofrequency. METHODS: Ten patients (90% men) with symptomatic atrial fibrillation (50% paroxystic type) that was refractory to drug therapy, with no heart disease that required concomitant surgical treatment, were submitted to arrhythmia ablation guided by thoracoscopy from May 2007 to May 2008. Clinical, laboratory and image variables were prospectively collected before, during surgery and at the postoperative follow-up. RESULTS: The surgery was carried out as planned in all patients. There was no intra-thoracic structure iatrogenic lesion or deaths. At the mean 6-month follow-up, 80% of the patients were free of atrial fibrillation. There was a significant improvement in the symptoms of New York Heart Association Functional Class heart failure (2.4 ± 0.5 to 1.6 ± 0.7; p=0.011). There was no evidence of pulmonary vein stenosis at the angiotomography in this series. CONCLUSION: The video-assisted surgery for the treatment of atrial fibrillation is reproducible and safe. There is a heart failure symptom evolution improvement after the surgery. FUNDAMENTO: La prevalencia de la fibrilación atrial, los gastos con el sistema de salud y la elevada morbilidad y mortalidad asociados a ésta, justifican la búsqueda de nuevos abordajes terapéuticos. OBJETIVO: Evaluar la reproducibilidad de la técnica quirúrgica, la seguridad y los resultados iniciales de la cirugía videoasistida para la ablación de la fibrilación atrial aislada con radiofrecuencia bipolar. MÉTODOS: Diez pacientes (90% hombres) con fibrilación atrial (50% paroxística) sintomática y refractaria a la terapia medicamentosa, sin enfermedad cardíaca que requiriera cirugía concomitante, fueron sometidos a la ablación de la arritmia guiada por toracoscopía en el período de mayor de 2007 a mayo de 2008. Variables clínicas, de laboratorio y de imagina se recolectaron prospectivamente antes, durante y en el seguimiento postoperatorio. RESULTADOS: La cirugía se realizó conforme lo planeado en todos los pacientes. No hubo lesión iatrogénica de estructuras intratorácicas u óbitos. En el seguimiento medio de seis meses, el 80% de los pacientes están libres de fibrilación atrial. Hubo mejora significativa de los síntomas de insuficiencia cardíaca clase funcional New York Heart Association (2,4 ± 0,5 para 1,6 ± 0,7; p = 0,011). No hubo evidencia de estenosis de venas pulmonares a la angiotomografía en esta serie. CONCLUSIÓN: La cirugía videoasistida para el tratamiento de la fibrilación atrial es reproducible y segura. Hay mejora evolutiva de los síntomas de insuficiencia cardíaca después de la cirugía.

The intracardiac echocardiography (ICE) offers a detailed visualization of the cardiac structures, in association with hemodynamic information, allowing the precise and real-time positioning of the catheters, decreasing the time of exposure to fluoroscopy and the monitoring of acute complications during the electrophysiological procedure (i.e., formation of thrombi, pericardial effusion, cardiac tamponade), Consequently, its use has progressively increased, mainly in the ablation of atrial fibrillation and ventricular arrhythmias. It has shown to be very useful in the ablation of atrial fibrillation by providing anatomic data on the left atrium and pulmonary veins, helping in transseptal punctures, locating the ostium and antrum of the pulmonary veins, monitoring tissue injury during radiofrequency (RF) use, preventing esophageal injury by monitoring the injuries caused by RF on the left atrial posterior wall and assessing the pulmonary vein flow.

The prevalence of atrial fibrillation, expenses with the healthcare system and the associated high morbidity and mortality have justified the search for new therapeutic approaches.To evaluate the reproducibility of the surgical technique, its safety and the initial outcome of the video-assisted surgery for the isolated atrial fibrillation ablation with bipolar radiofrequency.Ten patients (90% men) with symptomatic atrial fibrillation (50% paroxystic type) that was refractory to drug therapy, with no heart disease that required concomitant surgical treatment, were submitted to arrhythmia ablation guided by thoracoscopy from May 2007 to May 2008. Clinical, laboratory and image variables were prospectively collected before, during surgery and at the postoperative follow-up.The surgery was carried out as planned in all patients. There was no intra-thoracic structure iatrogenic lesion or deaths. At the mean 6-month follow-up, 80% of the patients were free of atrial fibrillation. There was a significant improvement in the symptoms of New York Heart Association Functional Class heart failure (2.4 + or - 0.5 to 1.6 + or - 0.7; p = 0.011). There was no evidence of pulmonary vein stenosis at the angiotomography in this series.The video-assisted surgery for the treatment of atrial fibrillation is reproducible and safe. There is a heart failure symptom evolution improvement after the surgery.